Naloxone (provided under the brand names Prenoxad and Nyxoid in the UK) is a medication used to reverse opioid overdose. Since 2015, this medication has been more widely available in the UK as a ‘take home’ emergency medication.
This website aims to be a hub for information, guidance, news and research on Take Home Naloxone (THN). The main focus is on THN in the UK, although we have included select pieces of information on the supply of naloxone internationally.
The U.S. is facing an unprecedented number of opioid-related overdose deaths, and an array of other countries have experienced increases in opioid-related fatalities. In the U.S., naloxone is increasingly distributed to first responders to improve early administration to overdose victims, but its cost-effectiveness has not been studied. Lay distribution, in contrast, has been found to be cost-effective, but rising naloxone prices and increased mortality due to synthetic opioids may reduce cost-effectiveness. We evaluate the cost-effectiveness of increased naloxone distribution to (a) people likely to witness or experience overdose (“laypeople”); (b) police and firefighters; (c) emergency medical services (EMS) personnel; and (d) combinations of these groups.
ACMD young people’s drug use and naloxone provision
Following advice in response to COVID-19, 3 public evidence gathering days which were being arranged by the ACMD to inform reports on young people’s drug use and naloxone provision have been postponed until further notice. We are instead inviting relevant stakeholders to provide written submissions to help support these workstreams.
A generation of people born in the 1960s and 1970s, known as Generation X, are dying from suicide or drug poisoning in greater numbers than ever. ONS data for England and Wales has shown that in the late 1980s to early 1990s, the age at which most people died by taking their own lives or drug poisoning was concentrated around this generation, when they were in their 20s.
Release surveyed each of the 152 local authority areas in England, as local authorities are responsible for commissioning drug services, which give out take-home naloxone. The report includes findings on the availability of take-home naloxone across local authority areas, the scale of take-home naloxone supply in community settings, and coverage among people who use opiates and opiate clients in drug treatment.
Virtual reality opioid overdose prevention programs can be just as effective as in-person training to give people the knowledge and confidence to administer naloxone, according to a study conducted by the University of Pennsylvania and the Philadelphia Department of Public Health.
This website has been made possible through the provision of an arm length/unrestricted educational grant from Ethypharm. Ethypharm do not control and are not liable for any of the content placed, or any of the claims that may be made, on this site.